<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="letter"><?properties open_access?><!-- Original-type: sc--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17667923</article-id><article-id pub-id-type="pmc">2360345</article-id><article-id pub-id-type="pii">6603913</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6603913</article-id><article-categories><subj-group subj-group-type="heading"><subject>Molecular Diagnostics</subject></subj-group></article-categories><title-group><article-title>Inhibitory KIR&#x02013;HLA receptor&#x02013;ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Leung</surname><given-names>W</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Handgretinger</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Iyengar</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Turner</surname><given-names>V</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Holladay</surname><given-names>M S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hale</surname><given-names>G A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1"><label>1</label><institution>Department of Hematology-Oncology, St Jude Children's Research Hospital</institution> Memphis, TN, <country>USA</country></aff><aff id="aff2"><label>2</label><institution>Department of Pathology, St Jude Children's Research Hospital</institution> Memphis, TN, <country>USA</country></aff><aff id="aff3"><label>3</label><institution>Department of Pediatrics, University of Tennessee Health Science Center</institution> Memphis, TN, <country>USA</country></aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:wing.leung@stjude.org">wing.leung@stjude.org</email></corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>07</month><year>2007</year></pub-date><pub-date pub-type="collection"><day>14</day><month>08</month><year>2007</year></pub-date><pub-date pub-type="ppub"><day>20</day><month>08</month><year>2007</year></pub-date><volume>97</volume><issue>4</issue><fpage>539</fpage><lpage>542</lpage><history><date date-type="received"><day>02</day><month>01</month><year>2007</year></date><date date-type="rev-recd"><day>30</day><month>04</month><year>2007</year></date><date date-type="accepted"><day>29</day><month>06</month><year>2007</year></date></history><copyright-statement>Copyright 2007, Cancer Research UK</copyright-statement><copyright-year>2007</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><abstract><p>Genes that encode killer Ig-like receptors (KIRs) and their HLA class I ligands segregate independently; thus, some individuals may express an inhibitory KIR gene but not its cognate ligand. We hypothesised that these patients with KIR&#x02013;HLA receptor&#x02013;ligand mismatch have a low risk of relapse after an autologous haematopoietic stem cell transplantation (HCT). Sixteen consecutive patients with lymphoma or solid tumour were enrolled onto a prospective study. They received high-dose busulphan and melphalan followed by autologous CD133<sup>&#x0002b;</sup> HCT. We found that 8 of the 16 patients experienced disease progression after autologous HCT, including 5 of the 6 patients (83&#x00025;) with no inhibitory KIR&#x02013;HLA mismatch and 3 of the 6 patients (50&#x00025;) with 1 mismatched pair; none of the 4 (0&#x00025;) patients with 2 mismatched pairs experienced disease progression. Survival analyses showed that inhibitory KIR&#x02013;HLA mismatch was the only significant prognostic factor (<italic>P</italic>=0.01). The potential applicability of the receptor&#x02013;ligand mismatch model to autologous HCTs and to patients with lymphoma or solid tumour is clinically significant because of the prevalence of the HCT procedure.</p></abstract><kwd-group><kwd>natural killer cells</kwd><kwd>solid tumour</kwd><kwd>lymphoma</kwd><kwd>autologous transplantation</kwd></kwd-group></article-meta></front><body><p>Human NK cells are regulated by killer Ig-like receptors (KIRs) that recognise specific groups of HLA class I alleles (<xref ref-type="other" rid="bib13">Lanier, 2005</xref>). Both KIRs and their HLA ligands exhibit tremendous population diversity, and the KIR genes on chromosome 19 and HLA genes on chromosome 6 segregate independently (<xref ref-type="other" rid="bib9">Hsu <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib20">Parham, 2005</xref>). Thus, many individuals have an inhibitory KIR gene but not its corresponding ligand, while others may have a certain KIR ligand but not its corresponding KIR (<xref ref-type="other" rid="bib16">Leung <italic>et al</italic>, 2004</xref>; <xref ref-type="other" rid="bib20">Parham, 2005</xref>).</p><p>In corroboration with these genetic findings, we found that the risk of relapse after haploidentical haematopoietic stem cell transplantation (HCT) in patients with haematologic malignancies was best predicted by a model taking into consideration the expression of inhibitory KIRs on the donor NK cells and the absence of corresponding KIR ligands in the recipient's HLA repertoire (a KIR&#x02013;HLA receptor&#x02013;ligand mismatch model) (<xref ref-type="other" rid="bib16">Leung <italic>et al</italic>, 2004</xref>). For those HCTs in which neither the donor nor the recipient had the cognate ligand for the donor's inhibitory KIRs, the patients were found to be at low risk of relapse. Indeed, autoreactive NK cell clones, which are KIR2DL2/2DL3<sup>&#x0002b;</sup>, 2DL1<sup>&#x02212;</sup>, and 3DL1<sup>&#x02212;</sup>, have been found in healthy donors who lack HLA-C<sup>Asn80</sup> (the ligand for KIR2DL2/2DL3), and NK cells from approximately 50&#x00025; of these individuals were cytotoxic against autologous CD34<sup>&#x0002b;</sup> cells (<xref ref-type="other" rid="bib8">Grau <italic>et al</italic>, 2004</xref>). Therefore, it is logical to examine the application of the receptor&#x02013;ligand mismatch model to autologous HCTs. Because lymphoid leukaemias and solid tumours such as neuroblastoma are susceptible to KIR&#x02013;HLA mismatched NK cell&#x02013;mediated lysis (<xref ref-type="other" rid="bib16">Leung <italic>et al</italic>, 2004</xref>, <xref ref-type="other" rid="bib14">2005a</xref>), we conducted a prospective study to test the hypothesis that patients with lymphoma or other solid tumour who receive autologous HCT have a low risk of relapse if KIR&#x02013;HLA mismatch(es) is present.</p><sec sec-type="methods"><title>PATIENTS AND METHODS</title><sec><title>Autologous HCT</title><p>All patients were enrolled onto an autologous HCT protocol approved by the Institutional Review Board, and the patients or their legal guardians gave the written informed consent. After enrolment, all patients received 10&#x02009;mcg&#x02009;kg<sup>&#x02212;1</sup> per day G-CSF for 5 days and then underwent leukapheresis for peripheral blood stem cell collection. Apheresis products were selected for CD133<sup>&#x0002b;</sup> cells by using the CliniMACS system for tumour-cell purging, except for two that had low initial cell count. Conditioning consisted of busulfan (37.5&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> per dose every 6&#x02009;h intravenously for 16 doses) and melphalan (70&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> per day for 2 days). After stem cell infusion, all patients received G-CSF, starting 5 days after HCT until ANC was &#x0003e;3000&#x02009;mm<sup>&#x02212;3</sup> for two consecutive days.</p></sec><sec><title>HLA and KIR typing</title><p>All samples were HLA typed by DNA methods as previously described (<xref ref-type="other" rid="bib16">Leung <italic>et al</italic>, 2004</xref>). KIR genotyping was performed by using a genotyping kit from Pel-Freez (now Dynal Biotech, Invitrogen, Carlsbad, CA, USA) and KIR phenotyping was determined by flow cytometry analysis, as some of the KIRs may not be expressed on the cell surface (<xref ref-type="other" rid="bib15">Leung <italic>et al</italic>, 2005b</xref>). Thus, a KIR was classified to be positive for a particular patient only if that KIR gene was tested positive by genotyping and was also found to be expressed by NK cells in phenotyping. The natural cytotoxicity of NK cells against K562 cells was determined by a standard europium release assay with a 40&#x02009;:&#x02009;1 (E&#x02009;:&#x02009;T) cell ratio (<xref ref-type="other" rid="bib16">Leung <italic>et al</italic>, 2004</xref>).</p></sec><sec><title>Statistical analysis</title><p>The cohort was divided into two risk groups based on the inhibitory KIR&#x02013;HLA receptor&#x02013;ligand model and cytotoxicity model, which have been described previously (<xref ref-type="other" rid="bib16">Leung <italic>et al</italic>, 2004</xref>). Briefly, a patient was classified as being at low risk by using the KIR&#x02013;HLA receptor&#x02013;ligand model if at least one of the inhibitory KIR genes expressed on the patient's NK cells did not recognise any of the HLA molecules in the patient's HLA ligand repertoire. The patients in the low-risk group were then further categorised by the number of receptor&#x02013;ligand mismatch pairs. The hypothesis was that a larger number of KIR&#x02013;HLA mismatch pairs would result in greater antitumour activity (<xref ref-type="other" rid="bib16">Leung <italic>et al</italic>, 2004</xref>). The cytotoxicity model measured the general cytotoxicity of engrafting NK cells against K562 cells (<xref ref-type="other" rid="bib16">Leung <italic>et al</italic>, 2004</xref>). The Perugia's KIR ligand incompatibility model was not used, because all grafts were ligand matched with the recipients by definition (ie, the KIR ligands present in the graft were identical to those in the patient in all autologous HCTs). Event-free survivals (EFSs) were estimated and compared by using the method of Kaplan&#x02013;Meier and log-rank statistics. Event-free survival was defined as the time from transplantation to disease progression or death, whichever occurred first. Because there was no transplant-related mortality, the EFSs were identical to progression-free survivals and there was no competing event in the evaluation of the cumulative incidences of disease progression. Cox's regression was used to assess hazard functions. Covariates included receptor&#x02013;ligand mismatch, type of malignancy, disease status at the time of HCT, number of CD133<sup>&#x0002b;</sup> cells in the graft, and natural cytotoxicity. Survivors were censored at a cut-off of 1 October 2006.</p></sec></sec><sec><title>RESULTS</title><p>Sixteen consecutive patients in a prospective study underwent autologous HCT. There was no transplant-related mortality (<xref rid="tbl1" ref-type="table">Table 1</xref>). Eight patients experienced disease progression after autologous HCT, including five of the six (83&#x00025;) patients with no inhibitory KIR&#x02013;HLA mismatch and three of the six (50&#x00025;) patients with one mismatched pair; none of the four (0&#x00025;) patients with two mismatched pairs experienced disease progression (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Survival analyses showed that KIR&#x02013;HLA mismatch was the only significant prognostic factor (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). The type and status of malignancy at the time of HCT, the number of CD133<sup>&#x0002b;</sup> cells in the graft, and the cytotoxicity model measuring the lysis of K562 cells by engrafting NK cells were not significant prognostic factors (<xref rid="tbl2" ref-type="table">Table 2</xref>). The median time to relapse for the patients in the high-risk category with no inhibitory KIR&#x02013;HLA mismatch was only 89 days (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), whereas that for patients in the low-risk group with mismatch has not yet been reached after a median follow-up of 812 days.</p><p>This cohort provides a unique opportunity not only to investigate the prognostic significance of the KIR&#x02013;HLA receptor&#x02013;ligand model, but also to examine the KIR ligand repertoires of patients with solid malignancy, because HLA typing is typically not performed for autologous HCTs. We found that five patients in this cohort were Cw7 homozygous, and four other patients were heterozygous for Cw7. The frequency of Cw7 homozygosity observed in this cohort was 31.3&#x00025; (95&#x00025; confidence limits, 11.0 and 58.7&#x00025;), which was significantly higher than that predicted by using data from the general population adjusted for ethnic group (8.6&#x00025;; <italic>P</italic>=0.009 by binomial exact test) (<xref ref-type="other" rid="bib1">Allele Frequencies in Worldwide Populations Website, 2006</xref>). Cw7 is a member of the HLA-C<sup>Asn80</sup> allotypes. Cancer susceptibility in individuals homozygous for HLA-C<sup>Asn80</sup>, as well as protective effect by HLA-C<sup>Lys80</sup>, was observed in cervical cancer and melanoma (<xref ref-type="other" rid="bib3">Carrington <italic>et al</italic>, 2005</xref>; <xref ref-type="other" rid="bib19">Naumova <italic>et al</italic>, 2005</xref>).</p></sec><sec><title>DISCUSSION</title><p>NK cells in our patients after autologous HCT were primarily derived from stem/progenitor cells, because mature NK cells were depleted <italic>in vivo</italic> and <italic>ex vivo</italic> by the myeloablative conditioning and CD133<sup>&#x0002b;</sup> cell&#x02013;selection procedure. During the period of receptor acquisition, subsets of NK cells may express a certain inhibitory KIR with no cognate ligand. Recent studies in healthy mice have demonstrated that NK cells expressing inhibitory receptors with no self-ligands exist (<xref ref-type="other" rid="bib7">Fernandez <italic>et al</italic>, 2005</xref>; <xref ref-type="other" rid="bib12">Kim <italic>et al</italic>, 2005</xref>). These cells are hyporesponsive in steady state, because they have not undergone the &#x02018;licensing' process (<xref ref-type="other" rid="bib12">Kim <italic>et al</italic>, 2005</xref>; <xref ref-type="other" rid="bib18">MacDonald, 2005</xref>). However, the hyporesponsive state of these &#x02018;unlicensed' NK cells is not permanent, as they can be activated easily in response to proinflammatory cytokines that activate almost all NK cells during infection (<xref ref-type="other" rid="bib2">Biron <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib12">Kim <italic>et al</italic>, 2005</xref>). Thus, the licensing effect was much less prominent among preactivated NK cells, a finding suggesting that the licensing requirement could be circumvented in specific situations (<xref ref-type="other" rid="bib12">Kim <italic>et al</italic>, 2005</xref>). The high-dose cytotoxic chemotherapy given to our patients may provide the proinflammatory setting that favours autoreactive NK cells against tumour cells that express high level of activating ligands (<xref ref-type="other" rid="bib4">Castriconi <italic>et al</italic>, 2004</xref>). Worthy of notice, the other transplant settings in this cohort were also reminiscent of those of our previous haploidentical cohort in which the KIR&#x02013;HLA receptor&#x02013;ligand model was first established; namely, NK cells were derived from highly purified stem cells (<xref ref-type="other" rid="bib16">Leung <italic>et al</italic>, 2004</xref>); mature T cells and B cells were extensively depleted to provide a lymphopenic environment (<xref ref-type="other" rid="bib21">Prlic <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib11">Jamieson <italic>et al</italic>, 2004</xref>); and there was no interference by graft-versus-host disease or its treatment (<xref ref-type="other" rid="bib17">Lowe <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib6">Cooley <italic>et al</italic>, 2005</xref>). All of these factors may contribute significantly to the prominent NK cell effects observed in this study.</p><p>The extension of the applicability of the KIR&#x02013;HLA receptor&#x02013;ligand model to autologous HCTs is clinically significant, as the number of autologous HCTs performed worldwide annually is twice that of allogeneic HCTs (<xref ref-type="other" rid="bib5">Center for International Blood and Marrow Transplant Research (CIBMTR) website, 2006</xref>). Haploidentical HCTs are performed only in a few centres, whereas autologous HCTs are offered in almost all the transplantation centres. Herein, we demonstrated for the first time that patients with inhibitory KIR&#x02013;HLA mismatch are at low risk of relapse after autologous HCT. Other novel observation is that the receptor&#x02013;ligand model may be applicable not only to patients with leukaemia (<xref ref-type="other" rid="bib16">Leung <italic>et al</italic>, 2004</xref>, <xref ref-type="other" rid="bib10">Hsu <italic>et al</italic>, 2005</xref>), but also to patients with lymphoma or solid tumour. One limitation of this study is that the number of patients was small for each disease category. Our novel findings, however, should stimulate future studies in other centres and in larger cohorts with uniform primary diseases. If confirmed, these results will have significant implications for prognostication and selection of patients for autologous HCT.</p></sec></body><back><ack><p>We thank Angela J McArthur, Ph.D., for scientific editing, and Margaret Swann for secretarial assistance. This work was supported in part by National Institutes of Health grant P30CA21765-24 (to WL), the Assisi Foundation of Memphis (to WL), and the American Lebanese Syrian Associated Charities (ALSAC).</p></ack><ref-list><ref id="bib1"><citation citation-type="other"><person-group person-group-type="author"><collab>Allele Frequencies in Worldwide Populations Website</collab></person-group><article-title/><year>2006</year>Accessed on November 25, 2006</citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Biron</surname><given-names>CA</given-names></name><name><surname>Nguyen</surname><given-names>KB</given-names></name><name><surname>Pien</surname><given-names>GC</given-names></name><name><surname>Cousens</surname><given-names>LP</given-names></name><name><surname>Salazar-Mather</surname><given-names>TP</given-names></name></person-group><article-title>Natural killer cells in antiviral defense: function and regulation by innate cytokines</article-title><source>Annu Rev Immunol</source><year>1999</year><volume>17</volume><fpage>189</fpage><lpage>220</lpage><!--PubMed citation query: 'Annu Rev Immunol||17|189||bib2|'--><pub-id pub-id-type="pmid">10358757</pub-id></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carrington</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Martin</surname><given-names>MP</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Schiffman</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Herrero</surname><given-names>R</given-names></name><name><surname>Rodriguez</surname><given-names>AC</given-names></name><name><surname>Kurman</surname><given-names>R</given-names></name><name><surname>Mortel</surname><given-names>R</given-names></name><name><surname>Schwartz</surname><given-names>P</given-names></name><name><surname>Glass</surname><given-names>A</given-names></name><name><surname>Hildesheim</surname><given-names>A</given-names></name></person-group><article-title>Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci</article-title><source>J Exp Med</source><year>2005</year><volume>201</volume><fpage>1069</fpage><lpage>1075</lpage><!--PubMed citation query: 'J Exp Med||201|1069||bib3|'--><pub-id pub-id-type="pmid">15809352</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Castriconi</surname><given-names>R</given-names></name><name><surname>Dondero</surname><given-names>A</given-names></name><name><surname>Corrias</surname><given-names>MV</given-names></name><name><surname>Lanino</surname><given-names>E</given-names></name><name><surname>Pende</surname><given-names>D</given-names></name><name><surname>Moretta</surname><given-names>L</given-names></name><name><surname>Bottino</surname><given-names>C</given-names></name><name><surname>Moretta</surname><given-names>A</given-names></name></person-group><article-title>Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction</article-title><source>Cancer Res</source><year>2004</year><volume>15</volume><fpage>9180</fpage><lpage>9184</lpage><!--PubMed citation query: 'Cancer Res||15|9180||bib4|'--></citation></ref><ref id="bib5"><citation citation-type="other"><person-group person-group-type="author"><collab>Center for International Blood and Marrow Transplant Research (CIBMTR)</collab></person-group><article-title/><year>2006</year>website:Accessed on November 25, 2006</citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cooley</surname><given-names>S</given-names></name><name><surname>McCullar</surname><given-names>V</given-names></name><name><surname>Wangen</surname><given-names>R</given-names></name><name><surname>Bergemann</surname><given-names>TL</given-names></name><name><surname>Spellman</surname><given-names>S</given-names></name><name><surname>Weisdorf</surname><given-names>DJ</given-names></name><name><surname>Miller</surname><given-names>JS</given-names></name></person-group><article-title>KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation</article-title><source>Blood</source><year>2005</year><volume>106</volume><fpage>4370</fpage><lpage>4376</lpage><!--PubMed citation query: 'Blood||106|4370||bib6|'--><pub-id pub-id-type="pmid">16131567</pub-id></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>NC</given-names></name><name><surname>Treiner</surname><given-names>E</given-names></name><name><surname>Vance</surname><given-names>RE</given-names></name><name><surname>Jamieson</surname><given-names>AM</given-names></name><name><surname>Lemieux</surname><given-names>S</given-names></name><name><surname>Raulet</surname><given-names>DH</given-names></name></person-group><article-title>A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules</article-title><source>Blood</source><year>2005</year><volume>105</volume><fpage>4416</fpage><lpage>4423</lpage><!--PubMed citation query: 'Blood||105|4416||bib7|'--><pub-id pub-id-type="pmid">15728129</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grau</surname><given-names>R</given-names></name><name><surname>Lang</surname><given-names>KS</given-names></name><name><surname>Wernet</surname><given-names>D</given-names></name><name><surname>Lang</surname><given-names>P</given-names></name><name><surname>Niethammer</surname><given-names>D</given-names></name><name><surname>Pusch</surname><given-names>CM</given-names></name><name><surname>Handgretinger</surname><given-names>R</given-names></name></person-group><article-title>Cytotoxic activity of natural killer cells lacking killer-inhibitory receptors for self-HLA class I molecules against autologous hematopoietic stem cells in healthy individuals</article-title><source>Exp Mol Pathol</source><year>2004</year><volume>76</volume><fpage>90</fpage><lpage>98</lpage><!--PubMed citation query: 'Exp Mol Pathol||76|90||bib8|'--><pub-id pub-id-type="pmid">15010286</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>KC</given-names></name><name><surname>Chida</surname><given-names>S</given-names></name><name><surname>Geraghty</surname><given-names>DE</given-names></name><name><surname>Dupont</surname><given-names>B</given-names></name></person-group><article-title>The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism</article-title><source>Immunol Rev</source><year>2002</year><volume>190</volume><fpage>40</fpage><lpage>52</lpage><!--PubMed citation query: 'Immunol Rev||190|40||bib9|'--><pub-id pub-id-type="pmid">12493005</pub-id></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>KC</given-names></name><name><surname>Keever-Taylor</surname><given-names>CA</given-names></name><name><surname>Wilton</surname><given-names>A</given-names></name><name><surname>Pinto</surname><given-names>C</given-names></name><name><surname>Heller</surname><given-names>G</given-names></name><name><surname>Arkun</surname><given-names>K</given-names></name><name><surname>O'Reilly</surname><given-names>RJ</given-names></name><name><surname>Horowitz</surname><given-names>MM</given-names></name><name><surname>Dupont</surname><given-names>B</given-names></name></person-group><article-title>Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes</article-title><source>Blood</source><year>2005</year><volume>105</volume><fpage>4878</fpage><lpage>4884</lpage><!--PubMed citation query: 'Blood||105|4878||bib10|'--><pub-id pub-id-type="pmid">15731175</pub-id></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jamieson</surname><given-names>AM</given-names></name><name><surname>Isnard</surname><given-names>P</given-names></name><name><surname>Dorfman</surname><given-names>JR</given-names></name><name><surname>Coles</surname><given-names>MC</given-names></name><name><surname>Raulet</surname><given-names>DH</given-names></name></person-group><article-title>Turnover and proliferation of NK cells in steady state and lymphopenic conditions</article-title><source>J Immunol</source><year>2004</year><volume>172</volume><fpage>864</fpage><lpage>870</lpage><!--PubMed citation query: 'J Immunol||172|864||bib11|'--><pub-id pub-id-type="pmid">14707057</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Poursine-Laurent</surname><given-names>J</given-names></name><name><surname>Truscott</surname><given-names>SM</given-names></name><name><surname>Lybarger</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>YJ</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>French</surname><given-names>AR</given-names></name><name><surname>Sunwoo</surname><given-names>JB</given-names></name><name><surname>Lemieux</surname><given-names>S</given-names></name><name><surname>Hansen</surname><given-names>TH</given-names></name><name><surname>Yokoyama</surname><given-names>WM</given-names></name></person-group><article-title>Licensing of natural killer cells by host major histocompatibility complex class I molecules</article-title><source>Nature</source><year>2005</year><volume>436</volume><fpage>709</fpage><lpage>713</lpage><!--PubMed citation query: 'Nature||436|709||bib12|'--><pub-id pub-id-type="pmid">16079848</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lanier</surname><given-names>LL</given-names></name></person-group><article-title>NK cell recognition</article-title><source>Annu Rev Immunol</source><year>2005</year><volume>23</volume><fpage>225</fpage><lpage>274</lpage><!--PubMed citation query: 'Annu Rev Immunol||23|225||bib13|'--><pub-id pub-id-type="pmid">15771571</pub-id></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>W</given-names></name><name><surname>Iyengar</surname><given-names>R</given-names></name><name><surname>Leimig</surname><given-names>T</given-names></name><name><surname>Holladay</surname><given-names>MS</given-names></name><name><surname>Houston</surname><given-names>J</given-names></name><name><surname>Handgretinger</surname><given-names>R</given-names></name></person-group><article-title>Phenotype and function of human natural killer cells purified by using a clinical-scale immunomagnetic method</article-title><source>Cancer Immunol Immunother</source><year>2005a</year><volume>54</volume><fpage>389</fpage><lpage>394</lpage><!--PubMed citation query: 'Cancer Immunol Immunother||54|389||bib14|'--><pub-id pub-id-type="pmid">15449041</pub-id></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>W</given-names></name><name><surname>Iyengar</surname><given-names>R</given-names></name><name><surname>Triplett</surname><given-names>B</given-names></name><name><surname>Turner</surname><given-names>V</given-names></name><name><surname>Behm</surname><given-names>FG</given-names></name><name><surname>Holladay</surname><given-names>MS</given-names></name><name><surname>Houston</surname><given-names>J</given-names></name><name><surname>Handgretinger</surname><given-names>R</given-names></name></person-group><article-title>Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors</article-title><source>J Immunol</source><year>2005b</year><volume>174</volume><fpage>6540</fpage><lpage>6545</lpage><!--PubMed citation query: 'J Immunol||174|6540||bib15|'--><pub-id pub-id-type="pmid">15879158</pub-id></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>W</given-names></name><name><surname>Iyengar</surname><given-names>R</given-names></name><name><surname>Turner</surname><given-names>V</given-names></name><name><surname>Lang</surname><given-names>P</given-names></name><name><surname>Bader</surname><given-names>P</given-names></name><name><surname>Conn</surname><given-names>P</given-names></name><name><surname>Niethammer</surname><given-names>D</given-names></name><name><surname>Handgretinger</surname><given-names>R</given-names></name></person-group><article-title>Determinants of antileukemia effects of allogeneic NK cells</article-title><source>J Immunol</source><year>2004</year><volume>172</volume><fpage>644</fpage><lpage>650</lpage><!--PubMed citation query: 'J Immunol||172|644||bib16|'--><pub-id pub-id-type="pmid">14688377</pub-id></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lowe</surname><given-names>EJ</given-names></name><name><surname>Turner</surname><given-names>V</given-names></name><name><surname>Handgretinger</surname><given-names>R</given-names></name><name><surname>Horwitz</surname><given-names>EM</given-names></name><name><surname>Benaim</surname><given-names>E</given-names></name><name><surname>Hale</surname><given-names>GA</given-names></name><name><surname>Woodard</surname><given-names>P</given-names></name><name><surname>Leung</surname><given-names>W</given-names></name></person-group><article-title>T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation</article-title><source>Br J Haematol</source><year>2003</year><volume>123</volume><fpage>323</fpage><lpage>326</lpage><!--PubMed citation query: 'Br J Haematol||123|323||bib17|'--><pub-id pub-id-type="pmid">14531915</pub-id></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname><given-names>HR</given-names></name></person-group><article-title>NK cell tolerance: revisiting the central dogma</article-title><source>Nat Immunol</source><year>2005</year><volume>6</volume><fpage>868</fpage><lpage>869</lpage><!--PubMed citation query: 'Nat Immunol||6|868||bib18|'--><pub-id pub-id-type="pmid">16116465</pub-id></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naumova</surname><given-names>E</given-names></name><name><surname>Mihaylova</surname><given-names>A</given-names></name><name><surname>Stoitchkov</surname><given-names>K</given-names></name><name><surname>Ivanova</surname><given-names>M</given-names></name><name><surname>Quin</surname><given-names>L</given-names></name><name><surname>Toneva</surname><given-names>M</given-names></name></person-group><article-title>Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals</article-title><source>Cancer Immunol Immunother</source><year>2005</year><volume>54</volume><fpage>172</fpage><lpage>178</lpage><!--PubMed citation query: 'Cancer Immunol Immunother||54|172||bib19|'--><pub-id pub-id-type="pmid">15248031</pub-id></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parham</surname><given-names>P</given-names></name></person-group><article-title>MHC class I molecules and KIRs in human history, health and survival</article-title><source>Nat Rev Immunol</source><year>2005</year><volume>5</volume><fpage>201</fpage><lpage>214</lpage><!--PubMed citation query: 'Nat Rev Immunol||5|201||bib20|'--><pub-id pub-id-type="pmid">15719024</pub-id></citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prlic</surname><given-names>M</given-names></name><name><surname>Blazar</surname><given-names>BR</given-names></name><name><surname>Farrar</surname><given-names>MA</given-names></name><name><surname>Jameson</surname><given-names>SC</given-names></name></person-group><article-title><italic>In vivo</italic> survival and homeostatic proliferation of natural killer cells</article-title><source>J Exp Med</source><year>2003</year><volume>197</volume><fpage>967</fpage><lpage>976</lpage><!--PubMed citation query: 'J Exp Med||197|967||bib21|'--><pub-id pub-id-type="pmid">12695488</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1"><label>Figure 1</label><caption><p>Significance of inhibitory KIR&#x02013;HLA receptor&#x02013;ligand mismatch. (<bold>A</bold>) Cumulative incidence (CI) of disease progression in patients with different numbers of receptor&#x02013;ligand mismatch pairs (<italic>P</italic>=0.02). (<bold>B</bold>) Event-free survival (EFS) of patients with receptor&#x02013;ligand mismatch and of those with no mismatch (<italic>P</italic>=0.01). Progression-free survival was identical to EFS because there was no transplant-related mortality.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="eps" xlink:href="6603913f1"/></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Characteristics of 16 consecutive patients who underwent autologous HCT and were grouped by their numbers of inhibitory KIR&#x02013;HLA receptor&#x02013;ligand mismatched pairs</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Disease</bold></th><th align="left" valign="top" charoff="50"><bold>Indication for HCT</bold></th><th align="left" valign="top" charoff="50"><bold>Disease status at the time of HCT</bold></th><th align="center" valign="top" charoff="50"><bold>No. of CD133<sup>&#x0002b;</sup> cells in the graft ( &#x000d7; 10<sup>6</sup>&#x02009;kg<sup>&#x02212;1</sup>)</bold></th><th align="center" valign="top" charoff="50"><bold>Natural cytotoxicity</bold> <bold>(&#x00025;)<sup>a</sup></bold></th><th align="center" valign="top" charoff="50"><bold>HLA-Bw</bold></th><th align="center" valign="top" charoff="50"><bold>HLA-C</bold></th><th align="center" valign="top" charoff="50"><bold>KIR mismatch<sup>a</sup></bold></th><th align="center" valign="top" charoff="50"><bold>Outcome</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">NB</td><td align="left" valign="top" charoff="50">Stage 4</td><td align="left" valign="top" charoff="50">VGPR</td><td align="center" valign="top" charoff="50">7.9</td><td align="center" valign="top" charoff="50">32.0</td><td align="center" valign="top" charoff="50">6/6</td><td align="center" valign="top" charoff="50">Asn80/Asn80</td><td align="center" valign="top" charoff="50">2DL1, 3DL1</td><td align="center" valign="top" charoff="50">Alive, NED</td></tr><tr><td align="left" valign="top" charoff="50">HD</td><td align="left" valign="top" charoff="50">Relapse</td><td align="left" valign="top" charoff="50">PR</td><td align="center" valign="top" charoff="50">5.5</td><td align="center" valign="top" charoff="50">13.1</td><td align="center" valign="top" charoff="50">6/6</td><td align="center" valign="top" charoff="50">Asn80/Asn80</td><td align="center" valign="top" charoff="50">2DL1, 3DL1</td><td align="center" valign="top" charoff="50">Alive, NED</td></tr><tr><td align="left" valign="top" charoff="50">HD</td><td align="left" valign="top" charoff="50">Relapse</td><td align="left" valign="top" charoff="50">CR</td><td align="center" valign="top" charoff="50">4.8</td><td align="center" valign="top" charoff="50">35.0</td><td align="center" valign="top" charoff="50">6/6</td><td align="center" valign="top" charoff="50">Asn80/Asn80</td><td align="center" valign="top" charoff="50">2DL1, 3DL1</td><td align="center" valign="top" charoff="50">Alive, NED</td></tr><tr><td align="left" valign="top" charoff="50">HD</td><td align="left" valign="top" charoff="50">Relapse</td><td align="left" valign="top" charoff="50">PR</td><td align="center" valign="top" charoff="50">5.0</td><td align="center" valign="top" charoff="50">16.8</td><td align="center" valign="top" charoff="50">6/6</td><td align="center" valign="top" charoff="50">Asn80/Asn80</td><td align="center" valign="top" charoff="50">2DL1, 3DL1</td><td align="center" valign="top" charoff="50">Alive, NED</td></tr><tr><td align="left" valign="top" charoff="50">NB</td><td align="left" valign="top" charoff="50">Stage 4</td><td align="left" valign="top" charoff="50">VGPR</td><td align="center" valign="top" charoff="50">7.6</td><td align="center" valign="top" charoff="50">13.5</td><td align="center" valign="top" charoff="50">4/6</td><td align="center" valign="top" charoff="50">Asn80/Asn80</td><td align="center" valign="top" charoff="50">2DL1</td><td align="center" valign="top" charoff="50">Alive, NED</td></tr><tr><td align="left" valign="top" charoff="50">NHL</td><td align="left" valign="top" charoff="50">Relapse</td><td align="left" valign="top" charoff="50">PR</td><td align="center" valign="top" charoff="50">2.1</td><td align="center" valign="top" charoff="50">ND</td><td align="center" valign="top" charoff="50">6/6</td><td align="center" valign="top" charoff="50">Asn80/Lys80</td><td align="center" valign="top" charoff="50">3DL1</td><td align="center" valign="top" charoff="50">Alive, NED</td></tr><tr><td align="left" valign="top" charoff="50">NHL</td><td align="left" valign="top" charoff="50">Relapse</td><td align="left" valign="top" charoff="50">PR</td><td align="center" valign="top" charoff="50">2.2</td><td align="center" valign="top" charoff="50">31.0</td><td align="center" valign="top" charoff="50">6/6</td><td align="center" valign="top" charoff="50">Asn80/Lys80</td><td align="center" valign="top" charoff="50">3DL1</td><td align="center" valign="top" charoff="50">Alive, NED</td></tr><tr><td align="left" valign="top" charoff="50">NB</td><td align="left" valign="top" charoff="50">Stage 4</td><td align="left" valign="top" charoff="50">VGPR</td><td align="center" valign="top" charoff="50">8.0</td><td align="center" valign="top" charoff="50">15.9</td><td align="center" valign="top" charoff="50">6/6</td><td align="center" valign="top" charoff="50">Asn80/Asn80</td><td align="center" valign="top" charoff="50">3DL1</td><td align="center" valign="top" charoff="50">Died of PD</td></tr><tr><td align="left" valign="top" charoff="50">NHL</td><td align="left" valign="top" charoff="50">Relapse</td><td align="left" valign="top" charoff="50">PR</td><td align="center" valign="top" charoff="50">5.9</td><td align="center" valign="top" charoff="50">15.6</td><td align="center" valign="top" charoff="50">4/6</td><td align="center" valign="top" charoff="50">Lys80/Lys80</td><td align="center" valign="top" charoff="50">2DL3</td><td align="center" valign="top" charoff="50">Died of PD</td></tr><tr><td align="left" valign="top" charoff="50">PNET</td><td align="left" valign="top" charoff="50">Metastasis</td><td align="left" valign="top" charoff="50">CR</td><td align="center" valign="top" charoff="50">5.3</td><td align="center" valign="top" charoff="50">16.5</td><td align="center" valign="top" charoff="50">4/6</td><td align="center" valign="top" charoff="50">Asn80/Asn80</td><td align="center" valign="top" charoff="50">2DL1</td><td align="center" valign="top" charoff="50">Died of PD</td></tr><tr><td align="left" valign="top" charoff="50">DSRCT</td><td align="left" valign="top" charoff="50">Metastasis</td><td align="left" valign="top" charoff="50">CR</td><td align="center" valign="top" charoff="50">5.4</td><td align="center" valign="top" charoff="50">18.4</td><td align="center" valign="top" charoff="50">4/6</td><td align="center" valign="top" charoff="50">Asn80/Lys80</td><td align="center" valign="top" charoff="50">None</td><td align="center" valign="top" charoff="50">Alive, NED</td></tr><tr><td align="left" valign="top" charoff="50">NHL</td><td align="left" valign="top" charoff="50">Relapse</td><td align="left" valign="top" charoff="50">PR</td><td align="center" valign="top" charoff="50">2.5</td><td align="center" valign="top" charoff="50">ND</td><td align="center" valign="top" charoff="50">4/6</td><td align="center" valign="top" charoff="50">Asn80/Lys80</td><td align="center" valign="top" charoff="50">None</td><td align="center" valign="top" charoff="50">Died of PD</td></tr><tr><td align="left" valign="top" charoff="50">ES</td><td align="left" valign="top" charoff="50">Relapse</td><td align="left" valign="top" charoff="50">PR</td><td align="center" valign="top" charoff="50">3.8</td><td align="center" valign="top" charoff="50">26.8</td><td align="center" valign="top" charoff="50">4/6</td><td align="center" valign="top" charoff="50">Asn80/Lys80</td><td align="center" valign="top" charoff="50">None</td><td align="center" valign="top" charoff="50">Died of PD</td></tr><tr><td align="left" valign="top" charoff="50">NB</td><td align="left" valign="top" charoff="50">Stage 4</td><td align="left" valign="top" charoff="50">VGPR</td><td align="center" valign="top" charoff="50">7.8</td><td align="center" valign="top" charoff="50">17.7</td><td align="center" valign="top" charoff="50">4/4</td><td align="center" valign="top" charoff="50">Asn80/Lys80</td><td align="center" valign="top" charoff="50">None</td><td align="center" valign="top" charoff="50">Died of PD</td></tr><tr><td align="left" valign="top" charoff="50">NB</td><td align="left" valign="top" charoff="50">Stage 4</td><td align="left" valign="top" charoff="50">PR</td><td align="center" valign="top" charoff="50">6.0</td><td align="center" valign="top" charoff="50">ND</td><td align="center" valign="top" charoff="50">6/6</td><td align="center" valign="top" charoff="50">Asn80/Lys80</td><td align="center" valign="top" charoff="50">None</td><td align="center" valign="top" charoff="50">Died of PD</td></tr><tr><td align="left" valign="top" charoff="50">NB</td><td align="left" valign="top" charoff="50">Stage 4</td><td align="left" valign="top" charoff="50">VGPR</td><td align="center" valign="top" charoff="50">8.0</td><td align="center" valign="top" charoff="50">15.0</td><td align="center" valign="top" charoff="50">4/6</td><td align="center" valign="top" charoff="50">Asn80/Lys80</td><td align="center" valign="top" charoff="50">None</td><td align="center" valign="top" charoff="50">Died of PD</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><label/><p>Abbreviations: CR=complete response; DSRBT=desmoplastic small round cell tumour; ES=Ewing's sarcoma; HD=Hodgkin's disease; NB=neuroblastoma; ND=not done; NED=no evidence of disease; NHL=non-Hodgkin's lymphoma; PD=progressive disease; PNET=primitive neuroectodermal tumour; PR=partial response; VGPR=very good partial response.</p></fn><fn id="t1-fn2"><label>a</label><p>Natural cytotoxicity indicates the specific lysis of K562 cells by blood mononuclear cells post-HCT and is used for the analysis of the cytotoxicity model; KIR&#x02013;HLA mismatch is determined by using the receptor&#x02013;ligand model.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Risk factor analysis for event-free survival</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Factor</bold></th><th align="center" valign="top" charoff="50"><bold>Hazard ratio</bold></th><th align="center" valign="top" charoff="50"><bold>95&#x00025; CI</bold></th><th align="center" valign="top" charoff="50"><bold><italic>P</italic>-value</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Receptor&#x02013;ligand model (match <italic>vs</italic> mismatch)</td><td align="center" valign="top" charoff="50">5.5</td><td align="center" valign="top" charoff="50">1.3&#x02013;24.2</td><td align="center" valign="top" charoff="50">0.01</td></tr><tr><td align="left" valign="top" charoff="50">Disease (lymphoma <italic>vs</italic> other solid tumours)</td><td align="center" valign="top" charoff="50">0.9</td><td align="center" valign="top" charoff="50">0.1&#x02013;7.9</td><td align="center" valign="top" charoff="50">0.94</td></tr><tr><td align="left" valign="top" charoff="50">Disease status (PR <italic>vs</italic> CR/VGPR)</td><td align="center" valign="top" charoff="50">1.3</td><td align="center" valign="top" charoff="50">0.3&#x02013;5.3</td><td align="center" valign="top" charoff="50">0.71</td></tr><tr><td align="left" valign="top" charoff="50">Cytotoxicity model</td><td align="center" valign="top" charoff="50">0.9</td><td align="center" valign="top" charoff="50">0.7&#x02013;1.1</td><td align="center" valign="top" charoff="50">0.42</td></tr><tr><td align="left" valign="top" charoff="50">Number of CD133<sup>&#x0002b;</sup> cells in graft</td><td align="center" valign="top" charoff="50">1.2</td><td align="center" valign="top" charoff="50">0.8&#x02013;1.8</td><td align="center" valign="top" charoff="50">0.43</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><label/><p>Abbreviations: CR=complete response; PR=partial response; VGPR=very good partial response.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>


